November 1, 2016 / 12:22 PM / in a year

BRIEF-AstraZeneca Canada announces Lynparza trial results

Nov 1 (Reuters) - AstraZeneca Plc

* AstraZeneca Canada - results from trial show clinically-meaningful, statistically-significant improvement of progression-free survival among patients

* Lynparza (olaparib) PHASE III SOLO-2 trial shows significant progression-free survival benefit for women with ovarian cancer Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below